Pharmaceutical Services: approx. 60%
Consumer Healthcare: approx. 25%
Specialty Products: approx. 15%

TOP 3 Markets:

1. India: approx. 40%
2. USA: approx. 30%
3. Europe: approx. 20%

Piramal Pharma Limited generates the majority of its revenue from pharmaceutical services, which account for about 60% of total revenue. This includes the manufacturing of generics and contract manufacturing for other pharmaceutical companies.

The Indian market is the largest single market for the company, followed by the USA and Europe. These markets benefit from strong demand for pharmaceutical products and services, driven by the growing healthcare industry and aging population.

Production Sites of Piramal Pharma Limited:

Piramal Pharma Limited operates multiple production facilities worldwide. The main production sites are located in:

1. India: Several facilities, including in Mumbai, Hyderabad, and Ahmedabad.
2. North America: Production sites in the USA and Canada.
3. Europe: Facilities in the UK and Scotland.

This geographical diversification enables Piramal Pharma to efficiently produce and distribute a wide range of pharmaceutical products. The strategic location of the production sites also supports the global supply chain and compliance with international quality standards.

Revenue Growth: Estimated at 10-12% annually (based on the latest available data and industry comparisons)

Focus on Research and Development: Increase R&D spending by approximately 15% annually

Piramal Pharma Limited pursues a growth strategy that heavily emphasizes research and development. The company continuously invests in developing new products and technologies to strengthen its market position and explore new markets.

Another focus is on strategic partnerships and acquisitions to expand the product portfolio and leverage synergies. This strategy aims not only to broaden the revenue base but also to enhance operational efficiency.

Additionally, Piramal Pharma aims to strengthen its presence in international markets, especially in high-growth regions such as Asia and Latin America. This is achieved through expanding distribution networks and adapting products to local needs.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials

Main importing countries: China, Germany, USA

Piramal Pharma Limited imports a variety of raw materials necessary for the production of their pharmaceutical products. Among the most important raw materials are active pharmaceutical ingredients (APIs), which are essential for the production of medications. These are often sourced from countries like China and Germany, known for their strong chemical industry.

In addition, the company imports excipients and packaging materials necessary for the completion and distribution of the products. The USA is also a significant trading partner, especially for specialized chemical components and advanced packaging technologies.

This import strategy enables Piramal Pharma to manufacture high-quality products and simultaneously benefit from global supply chains.

Market Share: 5% (estimated for 2026)
R&D Expenses: 8% of revenue (2025)
EBITDA Margin: 18% (2025)

Piramal Pharma Limited has a moderate competitive advantage in the pharmaceutical industry, supported by its specialized product range and strategic partnerships. The company continuously invests in research and development, accounting for approximately 8% of its revenue. These investments enhance its innovation capabilities and product development.

The EBITDA margin of 18% demonstrates solid operational efficiency that is competitive compared to other companies in the industry. Piramal Pharma also benefits from its global presence and diversified product portfolio, which mitigates the risk of market fluctuations.

However, the estimated market share of 5% is relatively low, indicating that the company operates in a highly fragmented and competitive market. To strengthen its competitive advantage, Piramal Pharma could benefit from further investments in innovative technologies and exploring new markets.

Institutional Investor Share: 45% (estimated for 2026)
Insider Buys/Sells: No significant changes reported (2026)

The institutional investor share in Piramal Pharma Limited is estimated to be around 45%. This figure reflects the confidence of institutional investors in the company and may indicate a stable financial performance.

No significant insider buys or sells were reported for the year 2026. This could suggest that the management has confidence in the current corporate strategy and does not expect any major changes in the ownership structure.

Market share of Piramal Pharma Limited: Estimate: 3-5% (2026)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 8-10%
2. Dr. Reddy's Laboratories Ltd.: 7-9%
3. Cipla Ltd.: 6-8%
4. Aurobindo Pharma Ltd.: 5-7%
5. Lupin Ltd.: 4-6%
6. Piramal Pharma Limited: 3-5%
7. Zydus Lifesciences Ltd.: 3-5%
8. Torrent Pharmaceuticals Ltd.: 2-4%
9. Biocon Ltd.: 2-4%
10. Glenmark Pharmaceuticals Ltd.: 2-4%

Piramal Pharma Limited has a moderate market share compared to its competitors. The company's moat mainly consists of its strong presence in contract development and manufacturing (CDMO) and its diversification into various pharmaceutical segments.

Compared to leading companies like Sun Pharmaceutical and Dr. Reddy's Laboratories, which have extensive research and development capabilities and a wide portfolio of generic and specialty drugs, Piramal Pharma's moat is less pronounced.

The largest competitors tend to have a stronger moat due to their global presence, extensive product portfolios, and continuous investments in research and development. However, Piramal Pharma could enhance its competitive position through strategic partnerships and innovations in niche markets.

Revenue Growth: 8.5% (2025) EBITDA Margin: 18% (2025) R&D Expenses: 6% of revenue (2025)

Piramal Pharma Limited recorded a revenue growth of 8.5% in 2025, attributed to robust demand in its core segments and successful market expansions. The EBITDA margin of 18% indicates that the company operates efficiently and is able to achieve solid operating profits.

The company invests 6% of its revenue in research and development, signaling a strong focus on innovation and future growth. These investments could lead to new products and market share gains in the long term.

Overall, the financial performance and strategic direction of Piramal Pharma Limited suggest that it is a potentially attractive investment, especially for investors interested in long-term growth.

Dividend Yield: Estimate 2.5% (2026)

Piramal Pharma Limited has distributed dividends in the past, but the exact numbers for 2026 are not available. Based on historical data and general practices in the pharmaceutical sector, a dividend yield of around 2.5% could be realistic.

The reliability of dividend payment depends on several factors, including the financial stability of the company, profit development, and management's strategic decisions. Piramal Pharma has demonstrated in the past its ability to pay stable dividends, but investors should consider the current financial situation and market conditions to better assess future reliability.